Darinaparsin - Solasia Pharma

Drug Profile

Darinaparsin - Solasia Pharma

Alternative Names: SP-02; SP-02L; Zinapar; ZIO-101

Latest Information Update: 24 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Texas A&M University; University of Texas M. D. Anderson Cancer Center
  • Developer Solasia Pharma; ZIOPHARM Oncology
  • Class Antineoplastics; Arsenicals; Oligopeptides; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Peripheral T-cell lymphoma
  • Discontinued Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 17 Aug 2018 Darinaparsin - Solasia Pharma is available for licensing in European Union, USA as of 17 Aug 2018. https://solasia.co.jp/en/
  • 17 Aug 2018 Solasia Pharma announced intention to submit NDA in Japan, Korea, Taiwan and Hong Kong
  • 19 Jun 2018 Discontinued - Phase-I for Lymphoma (Late-stage disease) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top